This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (24)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA

Reassessing Definitions of Success or Failure

Steven G. Deeks, MD

JAMA. 2001;286:224-226.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Left untreated, human immunodeficiency virus (HIV) replicates at a rapid rate, with the eventual production of billions of new virus particles per day. Given the propensity of HIV to mutate, the possibility exists that each newly produced virus contains at least 1 new mutation. Thus, from a darwinian perspective, ongoing viral replication in the presence of therapy should result in the rapid selection of drug resistance mutations and subsequent virologic rebound. These basic principles have provided the theoretical context for the "hit hard" therapeutic approach to HIV disease.¹ According to current treatment guidelines,^1-3 complete viral suppression should be the goal of therapy. Once therapy is initiated, plasma viremia, as measured by the concentration of viral RNA in plasma, should decrease to below the level of detection using the most sensitive assay available.^2-3 Persistent viremia suggests ongoing viral replication and treatment failure. The findings from 2 articles . . . [Full Text of this Article]

Author Affiliation: AIDS Program and Department of Medicine, University of California, San Francisco, and San Francisco General Hospital.

RELATED ARTICLES

Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy
Diane V. Havlir, Roland Bassett, Diane Levitan, Peter Gilbert, Pablo Tebas, Ann C. Collier, Martin S. Hirsch, Caroline Ignacio, Jon Condra, Huldrych F. Günthard, Douglas D. Richman, and Joseph K. Wong
JAMA. 2001;286(2):171-179.
ABSTRACT | FULL TEXT  

HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy
Monika Hermankova, Stuart C. Ray, Christian Ruff, Monique Powell-Davis, Roxann Ingersoll, Richard T. D'Aquila, Thomas C. Quinn, Janet D. Siliciano, Robert F. Siliciano, and Deborah Persaud
JAMA. 2001;286(2):196-207.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
Van Rompay et al.
J. Virol. 2006;80:6399-6410.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Type 1 env Evolves toward Ancestral States upon Transmission to a New Host
Herbeck et al.
J. Virol. 2006;80:1637-1644.
ABSTRACT | FULL TEXT  

Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation
Weber et al.
J. Clin. Microbiol. 2005;43:1395-1400.
ABSTRACT | FULL TEXT  

Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1
Zhang et al.
J. Virol. 2004;78:1718-1729.
ABSTRACT | FULL TEXT  

CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study
Kaufmann et al.
Arch Intern Med 2003;163:2187-2195.
ABSTRACT | FULL TEXT  

Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy
Frenkel et al.
J. Virol. 2003;77:5721-5730.
ABSTRACT | FULL TEXT